Cardiomyopathy
| Cardiomyopathy | |
|---|---|
| Classification and external resources | |
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium. |
|
| ICD-10 | I42.0 |
| ICD-9 | 425.4 |
| DiseasesDB | 2137 |
| MedlinePlus | 001105 |
| MeSH | D009202 |
Cardiomyopathy, which literally means "heart muscle disease", is the deterioration of the function of the myocardium (i.e., the actual heart muscle) for any reason. People with cardiomyopathy are often at risk of arrhythmia or sudden cardiac death or both.[1] Cardiomyopathy can often go undetected, making it especially dangerous to carriers of the disease. [2]
Although in theory the term "cardiomyopathy" could apply to almost any disease affecting the heart, in practice it is usually reserved for "severe myocardial disease leading to heart failure".[3]
Contents |
[edit] Classification
Cardiomyopathies can be categorized as extrinsic or intrinsic.[4]
- An extrinsic cardiomyopathy is a cardiomyopathy where the primary pathology is outside the myocardium itself. Most cardiomyopathies are extrinsic, because by far the most common cause of a cardiomyopathy is ischemia. The World Health Organization calls these specific cardiomyopathies:[4]
- An intrinsic cardiomyopathy is defined as weakness in the muscle of the heart that is not due to an identifiable external cause. This definition was used to categorize previously idiopathic cardiomyopathies although specific external causes have since been identified for many. For example, alcoholism has been identified as a cause for some forms of dilated cardiomyopathy. To make a diagnosis of an intrinsic cardiomyopathy, significant coronary artery disease should be ruled out (amongst other things). The term intrinsic cardiomyopathy does not describe the specific etiology of weakened heart muscle. The intrinsic cardiomyopathies consist of a variety of disease states, each with their own causes. Many intrinsic cardiomyopathies now have identifiable external causes including drug and alcohol toxicity, certain infections (including Hepatitis C), and various genetic and idiopathic (i.e., unknown) causes.
It is also possible to classify cardiomyopathies functionally, as involving dilation, hypertrophy, or restriction.[5]
[edit] Types
- Primary/intrinsic cardiomyopathies
- Genetic
- Mixed
- Dilated cardiomyopathy (DCM)
- Restrictive cardiomyopathy (RCM)
- Acquired
- Secondary/extrinsic cardiomyopathies
- Metabolic/storage
- Inflammatory
- Endocrine
- Toxicity
- Neuromuscular
- Nutritional diseases
- Other
- "Ischemic cardiomyopathy" is a weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease being the most common cause. Not supported by current cardiomyopathies classification schemes.[8][9]
[edit] Signs and symptoms
Symptoms and signs may mimic those of almost any form of heart disease. Chest pain is common. Mild myocarditis or cardiomyopathy is frequently asymptomatic; severe cases are associated with heart failure, arrhythmias, and systemic embolization. Manifestations of the underlying disease (e.g., Chagas' disease) may be prominent. Most patients with biopsy-proven myocarditis report a recent viral prodrome preceding cardiovascular symptoms.
EKG abnormalities are often present, although the changes are frequently nonspecific. A pattern characteristic of left ventricular hypertrophy may be present. Flat or inverted T waves are most common, often with low-voltage QRS complexes. Intraventricular conduction defects and bundle branch block, especially left bundle branch block, are also common. An echocardiogram is useful to detect wall motion abnormalities or a pericardial effusion. Chest radiographs can be normal or can show evidence of congestive heart failure with pulmonary edema or cardiomegaly.
[edit] Treatment
Treatment depends on the type of cardiomyopathy, but may include medication, implanted pacemakers, defibrillators, or ventricular assist devices (LVADs), or ablation. The goal of treatment is often symptom relief, and some patients may eventually require a heart transplant. Treatment of cardiomyopathy (and other heart diseases) using alternative methods such as stem cell therapy is commercially available but is not supported by convincing evidence. Due to the severity of the disease, treatment requires the use of numerous chemicals and drugs, which have to be taken for the rest of the patient's life.[10]
[edit] References
- ^ Kasper, Denis L. et al. (2005). Harrison's Principles of Internal Medicine, 16th edn. McGraw-Hill. ISBN 0-07-139140-1.
- ^ http://www.nlm.nih.gov/medlineplus/cardiomyopathy.html
- ^ Gabriel A. Adelmann (12 November 2010). Cardiology Essentials in Clinical Practice. Springer. pp. 158–. ISBN 9781849963046. http://books.google.com/books?id=o3j9bNpQ2poC&pg=PA158. Retrieved 11 November 2010.
- ^ a b Richardson, P. et al.; McKenna, W; Bristow, M; Maisch, B; Mautner, B; O'Connell, J; Olsen, E; Thiene, G et al (1996). "Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies". Circulation 93 (5): 841–2. doi:10.1161/01.CIR.93.5.841. PMID 8598070. (Full text)
- ^ Valentin Fuster; John Willis Hurst (2004). Hurst's the heart. McGraw-Hill Professional. pp. 1884–. ISBN 9780071432252. http://books.google.com/books?id=eWQAJDrVV7gC&pg=PA1884. Retrieved 11 November 2010.
- ^ Salazar-Schettino PM, Perera R, Ruiz-Hernandez AL, et al. (2009). "Chagas disease as a cause of symptomatic chronic myocardopathy in mexican children". Pediatr Infect Dis J 28 (11): 1011–3. doi:10.1097/INF.0b013e3181ad8425. PMID 19859016.
- ^ Sánchez-Guillén Mdel C, López-Colombo A, Ordóñez-Toquero G, et al. (2006). "Clinical forms of Trypanosoma cruzi infected individuals in the chronic phase of Chagas disease in Puebla, Mexico". Mem Inst Oswaldo Cruz 101 (7): 733–40. PMID 17160280.
- ^ Elliott, P.; Andersson, B.; Arbustini, E.; Bilinska, Z.; Cecchi, F.; Charron, P.; Dubourg, O.; Kuhl, U. et al (2007). "Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases". European Heart Journal 29 (2): 270–276. doi:10.1093/eurheartj/ehm342. PMID 17916581.
- ^ Maron, B. J.; Towbin, J. A.; Thiene, G.; Antzelevitch, C.; Corrado, D.; Arnett, D.; Moss, A. J.; Seidman, C. E. et al (2006). "Contemporary Definitions and Classification of the Cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention". Circulation 113 (14): 1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287. PMID 16567565.
- ^ http://www.ncbi.nlm.nih.gov/pubmed/21605722
[edit] External links
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||